Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Adjunctive use of plant-derived cannabidiol was associated with improved life expectancy in patients with glioblastoma multiforme, according to a case series published in Anticancer Research.
The study included 9 patients who were given a daily CBD dose of 400 mg in addition to standard treatment with maximal resection followed by radiochemotherapy.
At the time of article submission, the median survival time was 22.3 months (range 7 to 47 months), and all but one patient was alive. In comparison, the authors noted that median survival is typically 14 to 16 months in patients with this form of brain cancer.
References:
Likar R, Koestenberger M, Stultschnig M, Nahler G. Concomitant treatment of malignant brain tumours with CBD – a case series and review of the literature. Anticancer Res. 2019;39(10):5797-5801.
